Vezicle™ Liposomal Glutathione Powder 40%

Single-active liposomal powder designed for oxidation sensitivity, dispersion and sulphur-associated sensory burden. 40% reduced glutathione; immediate / non-modified.

Liposomal Glutathione Powder 40% supplies Reduced glutathione in a characterised phospholipid vesicle powder. It is intended as an independent formulation module for professional B2B use. Product-specific identity, assay, physical, microbiological, contaminant and stability controls are defined in the finished-product specification and verified by batch CoA.

What is Liposomal Glutathione Powder 40%?

Liposomal Glutathione Powder 40% supplies Reduced glutathione at 40% reduced glutathione in a characterised phospholipid vesicle powder; its release behaviour is Immediate / non-modified.

What is the technical specification?

The key public specification is 40% reduced glutathione with Immediate / non-modified release behaviour; batch acceptance follows the approved product-specific specification and analytical method.

What is the public composition?

The public composition identifies Reduced glutathione with a Food-grade phospholipid delivery system and powder carrier; exact proprietary excipient ratios and supplier details remain controlled.

Country of origin is stated in the controlled Country of Origin Statement. Supplier and manufacturing-site information are not published.

Which formulation problem does this ingredient address?

A characterised phospholipid vesicle system supports oxidation sensitivity, dispersion and sulphur-associated sensory burden while keeping the ingredient as a single-active, immediate/non-modified-release powder.

• Characterised liposomal structure
• single-active format
• dry-powder handling
• immediate/non-modified release.

Which applications are the best fit?

This ingredient is best suited to capsules, tablets, sachets and powder blends.

How should formulators process and evaluate it?

• Pre-disperse if required by the dosage form. Avoid prolonged exposure to heat, moisture, strong oxidants or extreme pH. Confirm process compatibility in the final matrix.
• Assess compatibility with minerals, strong oxidants, surfactants and high-temperature or extreme-pH processes.
• Confirm process compatibility, uniformity, stability and performance in the final matrix.

How is performance verified?

Performance is verified using approved product-specific methods and the controlled evidence listed below.

How should it be stored and handled?

Store tightly closed in original packaging in a cool, dry place, protected from heat, moisture and direct light. Free-flowing powder with product-specific colour and odour; see TDS and batch CoA.

Which technical and quality documents can be requested?

The current product-specific document set is confirmed for each enquiry according to qualification status, the applicable manufacturer and relevant batch. Controlled composition, characterisation or performance details may require an NDA where specified.

• Technical Data Sheet (TDS)
• Finished Product Specification
• Batch Certificate of Analysis (CoA)
• Safety Data Sheet (SDS)
• Allergen Statement
• GMO Statement
• Irradiation Statement
• BSE/TSE Statement
• Stability Documentation
• Composition / Ingredient Information
• Storage & Handling Information
• Microbiological Specification
• Heavy Metals Specification
• Country of Origin Statement
• Manufacturing / Quality Certificate
• Liposomal Characterisation Data

What must buyers confirm for regulatory and intended use?

Regulatory suitability depends on the intended use, dose and target market; the customer must confirm finished-product compliance.

How can B2B buyers evaluate and order it?

• Evaluation sample: 50 g — €35 ex VAT.
• May be credited once against the first commercial order for the same legal customer and product/project within 12 months
• Commercial MOQ is confirmed per quotation.
• Standard formats: 1 kg; 5 kg; 25 kg.
• Lead time is confirmed per quotation and depends on product and batch status, quantity, packaging, testing and release requirements, and destination.
• Custom strength available: Yes, subject to feasibility.
• Custom release available: No modified-release customisation in this platform.
• Private label / custom pack: Custom pack by quotation.
• Commercial terms confirmed by quotation.

What does NexaGens not claim?

No medicinal, disease-treatment or finished-product health claim is made. Liposomal terminology applies to the characterised supplied ingredient; performance in a finished product depends on formulation and processing. Finished-product classification, dose, permitted use, label declarations, nutrition or health claims and market compliance remain the customer’s responsibility.

Frequently asked questions

Which documentation can be requested?

The current product-specific document set is confirmed on request according to qualification status, the applicable manufacturer and relevant batch. Where available, product-specific characterisation data support the structural terminology.

Can this product be combined with other ingredients?

Yes. This product may be combined with other independent NexaGens formulation modules after compatibility and finished-product validation.

What is the release format?

The release format is immediate / non-modified.

For professional B2B food, food-supplement and formulation use only. Not for direct consumer use.